Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants priority review for obinutuzumab BLA

July 4, 2013

EMA gives Provenge a positive opinion

July 3, 2013

Seattle Genetics and Agensys set to develop additional antibody-drug conjugate

July 3, 2013

MorphoSys and Celgene create alliance to develop MOR-202 for multiple myeloma

July 1, 2013

VivaMab and ADC Therapeutics enter licensing agreement for ADC candidate

July 1, 2013

Japan approves Perjeta for HER2-positive inoperable or recurrent breast cancer

June 28, 2013

EMD Serono creates immune-oncology research and early development platform

June 28, 2013

Phase I study of MORAb-066 commences

June 27, 2013

Preliminary results from phase II trial of DN24-02 in urothelial cancer

June 27, 2013

Prima BioMed to begin three phase II trials of CVac

June 27, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...